Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Siekierka JJ et al. | Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. | 1991 | Transplant. Proc. | pmid:1721256 |
Morris RE | In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. | 1991 | Transplant. Proc. | pmid:1721257 |
Kobayashi M et al. | FK 506 assay past and present--characteristics of FK 506 ELISA. | 1991 | Transplant. Proc. | pmid:1721258 |
Warty VS et al. | Practical aspects of FK 506 analysis (Pittsburgh experience). | 1991 | Transplant. Proc. | pmid:1721259 |
Jusko WJ and D'Ambrosio R | Monitoring FK 506 concentrations in plasma and whole blood. | 1991 | Transplant. Proc. | pmid:1721260 |
Blanc P et al. | Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. | 1991 | Transplant. Proc. | pmid:1721288 |
Loréal O et al. | FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. | 1991 | Transplant. Proc. | pmid:1721289 |
McCauley J et al. | Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. | 1991 | Transplant. Proc. | pmid:1721290 |
McLachlan G et al. | Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721291 |
Woo J et al. | Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. | 1991 | Transplant. Proc. | pmid:1721319 |
Chen-Woan M et al. | Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721320 |
Fukuzawa M et al. | Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. | 1991 | Transplant. Proc. | pmid:1721321 |
Takaori K et al. | Effects of FK 506 on in vivo immunity in comparison to cyclosporine. | 1991 | Transplant. Proc. | pmid:1721322 |
Jordan ML et al. | Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. | 1991 | Transplant. Proc. | pmid:1721323 |
Motta I et al. | FK 506 favors the generation of memory T cells in vitro. | 1991 | Transplant. Proc. | pmid:1721324 |
Green M et al. | Infectious complications of pediatric liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721352 |
Torre-Cisneros J et al. | The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression. | 1991 | Transplant. Proc. | pmid:1721353 |
Paul AA et al. | CMV retinitis and the use of FK 506. | 1991 | Transplant. Proc. | pmid:1721354 |
Reyes J et al. | Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721355 |
Whiteside TL et al. | Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. | 1991 | Transplant. Proc. | pmid:1721356 |
Nalesnik MA et al. | Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. | 1991 | Transplant. Proc. | pmid:1703335 |
Armitage JM et al. | A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1703336 |
Gordon RD et al. | Liver transplantation under cyclosporine: a decade of experience. | 1991 | Transplant. Proc. | pmid:1703339 |
Todo S et al. | One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. | 1991 | Transplant. Proc. | pmid:1703340 |
McCauley J et al. | Changes in renal function after liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721385 |
Tauxe WN et al. | A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. | 1991 | Transplant. Proc. | pmid:1721386 |
McCauley J et al. | Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721387 |
Hossein-Nia M et al. | Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. | 1991 | Transplant. Proc. | pmid:1721388 |
Fukuzaki T et al. | Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. | 1991 | Transplant. Proc. | pmid:1721415 |
Tzakis AG et al. | FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721416 |
Masaoka T et al. | Phase II study of FK 506 for allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721417 |
Markus PM et al. | The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721418 |
Cooper MH et al. | The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. | 1991 | Transplant. Proc. | pmid:1721419 |
Ringe D | Immunosuppression. Binding by design. | 1991 | Nature | pmid:1710317 |
Tropschug M and Hofmann R | FK506 and protein kinase C. | 1991 | Nature | pmid:1710319 |
Albers MW et al. | Relationship of FKBP to PKCI-2. | 1991 | Nature | pmid:1710782 |
Stevens C et al. | The effects of immunosuppressive agents on in vitro production of human immunoglobulins. | 1991 | Transplantation | pmid:1710843 |
Metcalfe S and Milner J | Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. | 1991 | Transplantation | pmid:1710844 |
Fabrega AJ et al. | FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. | 1991 | Transplant. Proc. | pmid:1721447 |
Davies CB et al. | Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. | 1991 | Transplant. Proc. | pmid:1721448 |
Abu-Elmagd K et al. | FK 506: a new therapeutic agent for severe recalcitrant psoriasis. | 1991 | Transplant. Proc. | pmid:1721449 |
Nikolaidis NL et al. | Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. | 1991 | Transplant. Proc. | pmid:1721450 |
Starzl TE et al. | Notes on FK 506. | 1991 | Transplant. Proc. | pmid:1714647 |
Haba T et al. | Pathological and immunohistochemical examination in the rat treated with FK 506. | 1991 | Transplant. Proc. | pmid:1714649 |
Lautenschlager I et al. | Efficiency of FK 506 and CyA to prevent acute cellular rejection of pig liver allografts. | 1991 | Transplant. Proc. | pmid:1714650 |
Epand RF and Epand RM | The new potent immunosuppressant FK-506 reverses multidrug resistance in Chinese hamster ovary cells. | 1991 | Anticancer Drug Des. | pmid:1714737 |
Ochiai T et al. | [Immunosuppressive agents--advances of the developmental studies and the mode of action]. | 1991 | Nippon Rinsho | pmid:1715926 |
Jiang H et al. | Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. | 1991 | Eur Surg Res | pmid:1723683 |
Fung JJ et al. | Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. | 1991 | Transplant. Proc. | pmid:1703682 |
Fujino Y et al. | FK506 treatment of S-antigen induced uveitis in primates. | 1991 | Curr. Eye Res. | pmid:1717199 |